Protagenic Therapeutics, Inc.\new annual operating expenses
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Protagenic Therapeutics, Inc.\new Operating Expenses Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's operating expenses was $4.5M for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $4.5M | $1.9M | +73.65% |
| 2025 | 2025-03-31 | $2.6M | — | — |
| 2024 | 2024-12-31 | $5.7M | $1.2M | +25.93% |
| 2023 | 2023-12-31 | $4.5M | $969,186 | +27.24% |
| 2022 | 2022-12-31 | $3.6M | −$582,625 | −14.07% |
| 2021 | 2021-12-31 | $4.1M | $1.6M | +62.27% |
| 2020 | 2020-12-31 | $2.6M | $465,481 | +22.31% |
| 2019 | 2019-12-31 | $2.1M | −$227,997 | −9.85% |
| 2018 | 2018-12-31 | $2.3M | −$51,197 | −2.16% |
| 2017 | 2017-12-31 | $2.4M | $131,823 | +5.90% |
| 2016 | 2016-12-31 | $2.2M | $1.2M | +117.89% |
| 2015 · Dec 31 | 2015-12-31 | $1.0M | — | — |
| 2015 · Jun 30 | 2015-06-30 | $491,000 | −$484,000 | −49.64% |
| 2014 | 2014-06-30 | $975,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly operating expenses
Q2.11
Q3.11
Q2.11
Q3.11
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $961,247 | −$247,127 | −20.45% |
| Q4 2026 | 2026-03-31 | $1.3M | −$191,739 | −13.24% |
| Q3 2026 | 2025-12-31 | $925,103 | $523,702 | +130.47% |
| Q2 2026 | 2025-09-30 | $1.1M | $758,490 | +213.43% |
| Q1 2026 | 2025-06-30 | $1.2M | $886,543 | +275.47% |
| Q4 2025 | 2025-03-31 | $1.4M | −$290,251 | −16.70% |
| Q4 2024 | 2024-12-31 | $401,401 | −$810,825 | −66.89% |
| Q3 2024 | 2024-09-30 | $355,374 | −$1.1M | −75.18% |
| Q2 2024 | 2024-06-30 | $321,831 | −$821,911 | −71.86% |
| Q1 2024 | 2024-03-31 | $1.7M | $999,065 | +135.14% |
| Q4 2023 | 2023-12-31 | $1.2M | $556,448 | +84.85% |
| Q3 2023 | 2023-09-30 | $1.4M | $507,652 | +54.94% |
| Q2 2023 | 2023-06-30 | $1.1M | $507,068 | +79.64% |
| Q1 2023 | 2023-03-31 | $739,294 | −$601,982 | −44.88% |
| Q4 2022 | 2022-12-31 | $655,778 | −$205,441 | −23.85% |
| Q3 2022 | 2022-09-30 | $924,060 | $159,889 | +20.92% |
| Q2 2022 | 2022-06-30 | $636,674 | −$672,159 | −51.36% |
| Q1 2022 | 2022-03-31 | $1.3M | $135,086 | +11.20% |
| Q4 2021 | 2021-12-31 | $861,219 | $411,303 | +91.42% |
| Q3 2021 | 2021-09-30 | $764,171 | −$327,845 | −30.02% |
| Q2 2021 | 2021-06-30 | $1.3M | $819,890 | +167.69% |
| Q1 2021 | 2021-03-31 | $1.2M | $685,454 | +131.63% |
| Q4 2020 | 2020-12-31 | $449,916 | −$287,313 | −38.97% |
| Q3 2020 | 2020-09-30 | $1.1M | $902,394 | +475.89% |
| Q2 2020 | 2020-06-30 | $488,943 | −$16,321 | −3.23% |
| Q1 2020 | 2020-03-31 | $520,736 | −$133,279 | −20.38% |
| Q4 2019 | 2019-12-31 | $737,229 | $212,981 | +40.63% |
| Q3 2019 | 2019-09-30 | $189,622 | −$308,448 | −61.93% |
| Q2 2019 | 2019-06-30 | $505,264 | −$179,861 | −26.25% |
| Q1 2019 | 2019-03-31 | $654,015 | $47,331 | +7.80% |
| Q4 2018 | 2018-12-31 | $524,248 | −$184,535 | −26.04% |
| Q3 2018 | 2018-09-30 | $498,070 | −$28,962 | −5.50% |
| Q2 2018 | 2018-06-30 | $685,125 | $213,536 | +45.28% |
| Q1 2018 | 2018-03-31 | $606,684 | −$51,236 | −7.79% |
| Q4 2017 | 2017-12-31 | $708,783 | $152,507 | +27.42% |
| Q3 2017 | 2017-09-30 | $527,032 | $72,205 | +15.88% |
| Q2 2017 | 2017-06-30 | $471,589 | −$25,067 | −5.05% |
| Q1 2017 | 2017-03-31 | $657,920 | −$67,822 | −9.35% |
| Q4 2016 | 2016-12-31 | $556,276 | $405,276 | +268.39% |
| Q3 2016 | 2016-09-30 | $454,827 | $93,988 | +26.05% |
| Q2 2016 | 2016-06-30 | $496,656 | $395,693 | +391.92% |
| Q1 2016 · Mar 31 | 2016-03-31 | $725,742 | $675,821 | +1353.78% |
| Q4 2015 | 2015-12-31 | $151,000 | $14,000 | +10.22% |
| Q1 2016 · Sep 30 | 2015-09-30 | $360,839 | $242,839 | +205.80% |
| Q4 2015 · Jun 30 | 2015-06-30 | $100,963 | −$28,037 | −21.73% |
| Q3 2015 | 2015-03-31 | $49,921 | −$348,079 | −87.46% |
| Q2 2015 | 2014-12-31 | $137,000 | −$105,000 | −43.39% |
| Q1 2015 | 2014-09-30 | $118,000 | −$88,000 | −42.72% |
| Q4 2014 | 2014-06-30 | $129,000 | — | — |
| Q3 2014 | 2014-03-31 | $398,000 | — | — |
| Q2 2014 | 2013-12-31 | $242,000 | — | — |
| Q1 2014 | 2013-09-30 | $206,000 | — | — |
| Q3 2011 · Sep 30 | 2011-09-30 | $17.3M | $4.5M | +35.03% |
| Q2 2011 · Jun 30 | 2011-06-30 | $11.3M | −$4.0M | −26.19% |
| Q3 2011 · Sep 30 | 2010-09-30 | $12.8M | — | — |
| Q2 2011 · Jun 30 | 2010-06-30 | $15.3M | — | — |
Protagenic Therapeutics, Inc.\new operating expenses trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's operating expenses increased from $975,000 to $4.5M, a change of $3.5M. The latest reported quarter, Q1 2027, shows $961,247.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗